Baidu
map

肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

Lynparza治疗复发性BRCA突变的卵巢癌效果显著

2018-12-22 MedSci MedSci原创

LynparzaBRCA卵巢癌
关注

阿斯利康和默克公司近日公布了III期SOLO-3试验的结果，结果显示，在治疗复发性BRCA突变卵巢癌患者时，PARP抑制剂Lynparza（奥拉帕尼）与化疗相比，显著提高了曾有过两次或两次以上化疗患者的客观缓解率（ORR）。

阿斯利康和默克公司近日公布了III期SOLO-3试验的结果，结果显示，在治疗复发性BRCA突变卵巢癌患者时，PARP抑制剂Lynparza（奥拉帕尼）与化疗相比，显著提高了曾有过两次或两次以上化疗患者的客观缓解率（ORR）。默克研究实验室全球临床开发主管兼首席医疗官Roy Baynes表示，“继最近美国批准Lynparza作为某些BRCA突变晚期卵巢癌患者的一线维持治疗之后，SOLO-3的结果进一步证明了Lynparza在复发性晚期卵巢癌患者中的有效性”。

在该研究中，266名先前接受过治疗的BRCA1或BRCA2突变的卵巢癌患者被随机分配到Lynparza治疗组或医生选择的单药化疗组（包括紫杉醇、托泊替康、聚乙二醇化脂质体多柔比星或吉西他滨）。主要终点是ORR，由独立中心评价确定，关键的次要终点包括无进展生存（PFS）、第二次疾病进展或死亡的时间和总体存活率。阿斯利康全球药物开发主管兼首席医疗官Sean Bohen评论说：“我们对SOLO-3的结果感到非常兴奋，这是用于证明Lynparza在晚期卵巢癌中的有效性的第一个III期试验”。


原始出处：

http://www.firstwordpharma.com/node/1612840#axzz5aJrWexZu

本文系梅斯医学（MedSci）原创编译整理，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1909752, encodeId=0f291909e5256, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42518, encryptionId=8f1f42518d8, topicName=复发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Fri Dec 28 18:52:00 CST 2018, time=2018-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1418345, encodeId=79101418345b3, content=<a href='/topic/show?id=39fd3e036a' target=_blank style='color:#2F92EE;'>#BRCA突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3703, encryptionId=39fd3e036a, topicName=BRCA突变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=793f3344126, createdName=zhanglin3080, createdTime=Mon Dec 24 06:52:00 CST 2018, time=2018-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594040, encodeId=2f01159404070, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3684, encryptionId=63cc368459, topicName=BRCA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Mon Dec 24 06:52:00 CST 2018, time=2018-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046701, encodeId=f14a1046e0127, content=疗效只是效果的众多方面之一，还要看对患者的获益，包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Sat Dec 22 18:52:00 CST 2018, time=2018-12-22, status=1, ipAttribution=)]
    2018-12-28 hb2008ye

    #复发性#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1909752, encodeId=0f291909e5256, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42518, encryptionId=8f1f42518d8, topicName=复发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Fri Dec 28 18:52:00 CST 2018, time=2018-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1418345, encodeId=79101418345b3, content=<a href='/topic/show?id=39fd3e036a' target=_blank style='color:#2F92EE;'>#BRCA突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3703, encryptionId=39fd3e036a, topicName=BRCA突变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=793f3344126, createdName=zhanglin3080, createdTime=Mon Dec 24 06:52:00 CST 2018, time=2018-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594040, encodeId=2f01159404070, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3684, encryptionId=63cc368459, topicName=BRCA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Mon Dec 24 06:52:00 CST 2018, time=2018-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046701, encodeId=f14a1046e0127, content=疗效只是效果的众多方面之一，还要看对患者的获益，包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Sat Dec 22 18:52:00 CST 2018, time=2018-12-22, status=1, ipAttribution=)]
    2018-12-24 zhanglin3080

    #BRCA突变#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1909752, encodeId=0f291909e5256, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42518, encryptionId=8f1f42518d8, topicName=复发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Fri Dec 28 18:52:00 CST 2018, time=2018-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1418345, encodeId=79101418345b3, content=<a href='/topic/show?id=39fd3e036a' target=_blank style='color:#2F92EE;'>#BRCA突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3703, encryptionId=39fd3e036a, topicName=BRCA突变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=793f3344126, createdName=zhanglin3080, createdTime=Mon Dec 24 06:52:00 CST 2018, time=2018-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594040, encodeId=2f01159404070, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3684, encryptionId=63cc368459, topicName=BRCA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Mon Dec 24 06:52:00 CST 2018, time=2018-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046701, encodeId=f14a1046e0127, content=疗效只是效果的众多方面之一，还要看对患者的获益，包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Sat Dec 22 18:52:00 CST 2018, time=2018-12-22, status=1, ipAttribution=)]
    2018-12-24 智智灵药

    #BRCA#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1909752, encodeId=0f291909e5256, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42518, encryptionId=8f1f42518d8, topicName=复发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Fri Dec 28 18:52:00 CST 2018, time=2018-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1418345, encodeId=79101418345b3, content=<a href='/topic/show?id=39fd3e036a' target=_blank style='color:#2F92EE;'>#BRCA突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3703, encryptionId=39fd3e036a, topicName=BRCA突变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=793f3344126, createdName=zhanglin3080, createdTime=Mon Dec 24 06:52:00 CST 2018, time=2018-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594040, encodeId=2f01159404070, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3684, encryptionId=63cc368459, topicName=BRCA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Mon Dec 24 06:52:00 CST 2018, time=2018-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046701, encodeId=f14a1046e0127, content=疗效只是效果的众多方面之一，还要看对患者的获益，包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Sat Dec 22 18:52:00 CST 2018, time=2018-12-22, status=1, ipAttribution=)]
    2018-12-22 CHANGE

    疗效只是效果的众多方面之一，还要看对患者的获益，包括生活质量等因素共同决定效果的

    0

相关资讯

NICE否定了阿斯利康的PARP抑制剂Lynparza在卵巢癌维持治疗中的应用

美国国家健康与护理专业研究所（NICE）近日发布了一项针对阿斯利康的PARP抑制剂Lynparza（olaparib）用于复发性铂敏感性晚期上皮性卵巢癌维持治疗的意见，认为Lynparza的维持治疗不具备成本效益。

欧盟监管机构扩大了Lynparza的应用范围

欧洲监管机构已批准阿斯利康和MSD 的Lynparza片剂及新剂量方案来治疗更多的卵巢癌患者。Lynparza（olaparib）片剂已被批准用作铂类敏感复发（PSR）高级别，上皮性卵巢癌，输卵管癌或原发性腹膜癌患者的维持治疗，这些患者无论BRCA状态如何，对铂类药物完全应答或部分应答。该药物最初于2015年在欧洲获得胶囊制剂批准，但仅限于五分之一的患有BRCA突变的卵巢癌女性。无论BRCA状态如

Baidu
map
Baidu
map
Baidu
map